You are here

C03

Rebecca Eberhardt

2010 - 2014 Study of Molecular Medicine (BSc), Albert-Ludwigs-University of Freiburg
2013 Semester abroad, University of New South Wales, Sydney, Australia
2014 Bachelor thesis in Molecular Medicine, Albert-Ludwigs-University of Freiburg
2014 - 2016 Study of Molecular Medicine (MSc), Albert-Ludwigs-University of Freiburg
2016 Master thesis in Molecular Medicine, Albert-Ludwigs-University of Freiburg

Anna-Lena Geißler

2012 Diploma thesis at Novartis Institutes for Biomedical Research, Department of Autoimmunity, Transplantation & Inflammation, Basel, CH
2013 Postgraduate traineeship at Novartis Institutes for Biomedical Research, Department of Oncology, Basel, CH
2013 - present PhD student in the lab of Prof. Dr. Silke Laßmann, Department of Pathology, University Freiburg Medical Center and German Cancer Research Center (DKFZ), Heidelberg
2014 - 2015

Theresa Ahrens

2006 - 2011 Study of Molecular Medicine, Albert-Ludwigs-University of Freiburg
2011 Diploma thesis in Molecular Medicine, Albert-Ludwigs-University of Freiburg
2011 - 2012 PhD student in the lab of Dr. Meike Burger, Department of Haematology and Oncology, University Freiburg Medical Centre
2012 - present PhD student in the lab of Prof. Dr. Silke Laßmann, Institute of Pathology, University Freiburg Medical Centre
2015

Silke Laßmann

1991 - 1994 Study of Physiology, Graduation Bachelor of Science (1994), King’s College, University of London, UK
1994 - 1997 PhD work, Dept. of Neuroimmunology, Max Planck Institute for Neurobiology, Martinsried, Germany and External PhD Student, University of London, UK
1998 Graduation PhD, University of London, UK
1998 - 1999 Postdoctoral fellow, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, USA

C03 Epigenetic regulation of esophageal cancer

Esophageal cancers still represent a major challenge in interdisciplinary oncology. This project explores the epigenetic regulation of oesophageal cancers with respect to its pathobiology and therapeutic potential. We shall evaluate how histone modifiers guide squamous to intestinal cell differentiation in the development of oesophageal adenocarcinomas and establish in a genome-wide approach patterns of histone marks, transcriptomes, and mutational profiles. This project aims to validate epigenetic inhibitors for oesophageal cancer in a preclinical setting.

Subscribe to RSS - C03